Suven Life Sciences (Suven) has received product patents from Australia (2009355487), South Korea (10-1376145) and China (CN 102753540B) corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases and these patents are valid through 2029, 2029 and 2030 respectively. The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 17 granted patents from Australia, 13 granted patents from South Korea and 13 product patents from China. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for MDD with high unmet medical need with huge market potential globally,” says Venkat Jasti, Chief Executive Officer, Suven.
EP News Bureau– Mumbai